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Abbreviations 
 
ABI Acute Brain Injury 
BMT Best Medical Therapy 
CI Confidence Interval 
CSF Cerebrospinal fluid 
DC Decompressive craniectomy 
GCS Glasgow Coma Scale 
GOS Glasgow Outcome Scale 
GOS-E Extended Glasgow Outcome Scale 
ICHn Intracranial hypertension 
ICP Intracranial pressure 
IV Inverse variance 
MCI Malignant middle-cerebral-artery infarction 
mRS Modified Rankin Scale 
NOS Newcastle- Ottawa Scale 
NRT Non-randomised trials 
OR Odds ratio 
PICO population, intervention, control, and outcomes 
QoL Quality of Life 
RCT Randomised controlled trials 
RoB Risk of bias 
 
 
 
 ABSTRACT 
Background Malignant infarction of the middle-cerebral-artery (MCI) is life threatening. It 
is associated with a mortality as high as 80% and survival often at the expense of serious 
disability. Limited success of medical therapies has resulted in decompressive craniectomy 
(DC) being increasingly used as a treatment for MCI, though evidence of its efficacy is 
inconclusive. In this study, the efficacy of DC in improving survival, or survival free of 
severe disability, was assessed.  
 
Methods A meta-analysis was performed to approximate the efficacy of DC for treating 
MCI, considering age and time-to-surgery. A systematic literature review was conducted on 
Medline, Embase and Cochrane library databases to 01 August 2018. Death and severe 
disability at 3, 6, 12 and 36 months follow-up were assessed, comparing best medical therapy 
with DC. 
 
Results 18 studies were eligible for inclusion and represented 987 individuals who received 
DC. Nine of these were RCTs (n=374 DC). Early DC (<48h from onset of stroke) reduced 
mortality (OR=0.18, 95%CI=0.11, 0.29; P<0.00001) but not unfavourable outcome 
(modified Rankin Scale (mRS)>4) (OR=1.38, 95%CI=0.47, 4.11; P=0.56) at 12 months 
follow-up. This survival benefit was maintained regardless of age. 
 
Conclusion Early DC reduces mortality but does not appear to improve favourable outcomes 
in patients aged younger or older than 60 years following MCI. RCTs incorporating quality 
of life assessments are warranted for MCI patients, in addition to defining the optimal timing 
and benefits of DC in older patients. 
Funding None 
INTRODUCTION 
Acute brain injury (ABI), defined as injury to the brain that occurs after birth, is one of the 
leading causes of death and disability in adults worldwide. 1,2 Malignant stroke is a common 
cause of ABI. In a subgroup of patients with supra-tentorial stroke (approximately 1-10%), 
malignant middle cerebral artery infarctions (MCI) can occur. 3 These patients develop 
space-occupying brain oedema resulting in raised intracranial pressure (ICP), with 
subsequent ischaemic cell death and brain herniation. The prognosis is poor, with mortality 
as high as 70-80% and majority of survivors left with severe disabilities. 4,5  
The poor outcome is, at least in part, attributed to intracranial hypertension (ICHn), defined 
as ICP greater than 15-20mmHg. 6 Conventional treatment worldwide is aimed at reducing 
ICP using head elevation, osmotic agents, controlled hyperventilation, hypothermia and 
sedatives.7 Once brain swelling is sufficient to produce clinical and radiological signs, 
however, case-fatality is higher, despite optimal medical treatment. 8,9 Decompressive 
craniectomy (DC), with removal of cranium and subsequent durotomy/duroplasty, is an 
aggressive approach shown to reduce ICP and improve blood flow to ischaemic tissue in 
patients with refractory ICHn. 10,11 
Although DC is effective in reducing ICP it is accompanied by a myriad of non-trivial 
complications. 12 More importantly, there is a concern that survivors suffer permanent severe 
disability. A pooled analysis of randomised controlled trials (RCTs) showed that DC 
significantly reduced mortality and improved favourable outcome defined as modified 
Rankin scale (mRS)  3 in patients with MCI. 13 However, the inclusion of HAMLET trial 
showed a non-significant benefit associated with DC (mRS  4). 14 Moreover, important 
questions regarding the effect of patient age, timing of surgery and the issue of defining a 
 The present systematic review and meta-analysis of all available studies aimed to establish 
the effectiveness of DC on mortality and associated long-term outcomes in patients following 
MCI, with special consideration of patient age and optimum timing for surgery.  
METHODS 
A systematic literature review was conducted on MEDLINE, EMBASE, Cochrane library 
database and Controlled Trials metaRegister to define the role of DC in patients with MCI. 
Details of the search strategies that incorporated search criteria used by a previous Cochrane 
review 14 are given in Supplementary File 1. The last search update was 1st of August 2018. 
The titles, abstracts and keywords of relevant articles were examined to assess for eligibility, 
followed by screening of reference lists from retrieved articles to identify additional studies. 
The study selection process was performed according to the guidelines of PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and documented 
using a PRISMA flow diagram (Figure 1). 15  
 
Study Eligibility 
All clinical trials were eligible for inclusion, with no restriction on language or time of 
publication. The inclusion criteria were: 1) studies including adult patients over 18 years of 
age with MCI. MCI was defined as patients with acute ischaemic infarction with space-
occupying cerebral oedema, as evident on radiology; 2) studies comparing DC to medical 
treatment alone as control. Medical treatment or best medical therapy (BMT) was defined as 
non-surgical therapies to control ICP such as hyperosmolar solutions, sedation and paralysis, 
hyperventilation, barbiturates, and moderate hypothermia. Cerebrospinal fluid (CSF) 
drainage in patients with ICP monitoring was also regarded as a medical therapy 6 ; 3) 
primary outcomes assessed were death and disability defined by mRS or Glasgow outcome 
scale (GOS)/ extended-GOS (GOS-E) (if mRS score was unavailable), or a description of 
level of independence, at 3, 6, 12 or 36 months follow-up.  
 
Exclusion criteria were: 1) no comparison with medical treatment group; 2) unavailability of 
outcome data in an extractable format such as odds ratios (OR), relative risks, or results from 
which these could be calculated, at 3, 6, 12, or 36 months follow-up; and 3) reviews, meta-
analysis, guidelines, case reports, letters to editor, comments, duplicate studies. 
 
Data Extraction 
The following data were extracted and tabulated from MCI studies into standardised data 
extraction forms by two authors independently: study design, sample size, patient eligibility 
criteria, patient demographics such as age and gender, surgical procedure, National Institute 
of Health Stroke Scale (NIHSS) score, vascular territories and site of infarction, presence of 
preoperative clinical signs of herniation, time to surgical decompression, neurological 
outcomes as measured by mRS or GOS, mortality rates and duration of follow-up. 
Discrepancies were resolved by discussion between all authors.  
 
Quality assessment 
Each study underwent a quality assessment by two authors independently. For the RCTs the 
 16 was used to assess selection bias, attrition 
bias, performance bias, detection bias, and reporting bias. The limitation of NRTs falling 
short of full randomisation when allocating individuals to treatment group is recognised, and 
a careful assessment of RoB in NRT methodology was conducted. In particular, assessment 
of selection bias, bias due to confounding, and bias in measurement of interventions, was 
made using a modified version of Newcastle-Ottawa scale (NOS). 17  
Outcome 
The primary outcome measures evaluated in this meta-analysis were: 1) death at 3 months, 6 
months, 12 months and 36 months for MCI patients undergoing DC or BMT, and 2) 
unfavourable outcome defined as mRS score of >4. 18. Conventionally, an mRS score of 4 is 
included in the unfavourable outcome category and defines moderately severe disability 
where patients require assistance with walking and attending own bodily needs. An mRS of 5 
indicates severe disability; bedridden, incontinent, requiring nursing care and attention. 
Given that survival following MCI with no or slight disability is rare, investigators of recent 
RCTs include an mRS of 4 in the favourable outcome category. 19 Thus, data processed in the 
present study reflects this change for purposes of standardisation. 
 
Statistical analysis 
A summary of dichotomous outcome data in the form of odds ratios (ORs) and their 
corresponding 95% confidence intervals (CIs) were calculated. These were combined by a 
random effects meta-analysis model using the inverse variance (IV) method for pooled OR, 
followed by the Z-test to evaluate statistical significance (a p-value of less than 0.05 was 
considered statistically significant). The heterogeneity between studies was assessed using 
Chi-squared statistical test and I2 statistic, where a p<0.10 was considered to be statistically 
significant. I2 values up to 60% referred to moderate heterogeneity. 20 Sensitivity analyses 
were performed to investigate heterogeneity for all statistically significant findings. 
Assessment of publication bias was conducted by qualitative evaluation of funnel plots for 
asymmetry. All statistical analyses were performed using Review Manager 5.3 (RevMan) 
(Nordic Cochrane Centre) and reviewed by an information data analyst (HW).     
  
RESULTS 
Figure 1 presents the process from study identification (24,950 records) to selection. Of the 
24,950 records identified initially, the majority were excluded because they were reviews, 
case reports, duplicates, comments or irrelevant patient meet our population, intervention, 
control, and outcomes (PICO) criteria. Further, full texts were analysed and 18 studies 
comprising of nine RCTs and nine NRTs satisfied our inclusion criteria. These included 497 
patients in the surgery group and 486 patients in the conservative group. Of these nine were 
RCTs (379 patients) and nine were NRTs with (613 patients). The main study characteristics 
are summarised in Table 1. 
 
Assessments for RoB in nine RCTs and nine NRTs are summarised in Supplementary Table 
S1 and S2. Briefly, randomisation methods were adequately described in eight studies and 
allocation concealment in two studies. The main issues with RCTs were in reference to lack 
of allocation concealment, blinding of outcome assessment, and early termination of trials 
due to observation of large effects early. 12,13,19,21 Only 12 patients in the MCI studies 19,22,23 
were lost to follow up. Therefore, no attrition adjustments were required. The assessment of 
RoB in NRTs showed minimal risk of bias in all studies (>6/9 points on the Newcastle-
Ottawa Scale). 
 
Decompressive Craniectomy in Malignant Cerebral Infarction.  
Primary outcome: death at the end of follow-up 
Figure 2a presents a forest plot showing the pooled results of 18 studies for risk of death 
associated with DC versus BMT in patients with MCI. The pooled results of five studies at 3 
months (OR 0.17 95%CI 0.07-0.44; p=0.0002; I2=40%), 11 studies at 6 months (OR 0.25 
95%CI 0.14-0.43; p<0.00001; I2=54%), eight studies at 12 months (OR 0.18 95%CI 0.11-
0.29; p<0.00001; I2= 0%), and one study at 36 months (OR 0.21 95%CI 0.07-0.61); p = 
0.004) suggest a statistically significant association between DC and reduced risk of death.  
 
Primary outcome measure: unfavourable outcome 
A forest plot showing the pooled results for risk of unfavourable outcome (defined as mRS 
=5) associated with DC versus BMT in patients with MCI is shown in Figure 2b. The pooled 
results of three studies at 3 months (OR 0.53 95%CI 0.19-1.46; p = 0.22; I2= 0; p = 0.22), 
eight studies at 6 months (OR 1.03 95%CI 0.43-2.47; p = 0.94; I2=58%), and seven studies at 
12 months (OR 1.38 95%CI 0.47-4.11; p = 0.56; I2= 39%) suggested there was no significant 
difference between DC and BMT in terms of proportion of survivors with an unfavourable 
outcome. One study at 3 years also reflected this trend. 
 
Subgroup analysis of outcomes at 6 months: age <60 versus age >60 years 
Figure 3 presents the subgroup analysis, stratified by age. DC significantly reduced mortality 
in younger patients (OR 0.28 95% CI 0.15, 0.54; p=0.0001; I2=12%) and older patients OR 
0.14 95%CI 0.07, 0.28; p<0.00001; I2 10%) at 6 months follow-up. No significant difference 
in unfavourable outcome was found in younger (OR 0.99 95%CI 0.18,5.53; p=0.99; I2= 
61%) or older patients (OR 0.66 95%CI 0.24, 1.85; p=0.43; I2= 0%). 
 
Subgroup analysis of outcomes associated with early (<48hours) versus late DC (>48 
hours) 
Table 2 presents the subgroup analysis, stratified by timing of DC.  Early DC (<48 hours) 
significantly reduced mortality at 3 months follow up (OR 0.10, 95%CI 0.04, 0.23, 
p<0.00001), 6 months follow up (OR 0.22 95%CI 0.13, 0.39, p<0.00001), 12 months follow-
up (OR 0.15, 95%CI 0.09, 0.26, p<0.00001), and 3 years follow-up (OR 0.09 95%CI 0.02, 
0.40, p=0.002). However, early DC did not demonstrate a significant decrease in proportion 
of patients with an unfavourable outcome at any of the follow up periods. DC performed 
after 48 hours following MCI was not associated with improved outcomes at any of the 
follow up periods. 
 
Heterogeneity and sensitivity analyses for mortality and unfavourable outcome in MCI 
patients 
A sensitivity analysis of the MCI studies was performed to investigate the heterogeneous 
results at 6 months for mortality (I2= 54%) and unfavourable outcome (I2= 58%) (Table 3). 
Exclusion of NRTs resulted in reduction of heterogeneity of pooled results for both mortality 
(I2= 18%) and unfavourable outcome (I2= 0%) to acceptable levels.  
 
Assessment of publication bias  
Assessment of publication bias was carried out using funnel plots. The OR were plotted on a 
logarithmic scale to ensure that the results of same magnitude but opposite directions were 
spaced equidistant from 1.0. The funnel plots did not demonstrate any obvious asymmetry 
(Figure 4). 
 
DISCUSSION 
Evidence from eight studies in our pooled analysis demonstrates a significant survival 
advantage associated with DC in patients of all ages, when performed within 48 hours of 
onset of stroke. However, early DC may not reduce poor functional outcome in survivors, 
and DC performed after this time may not reduce mortality or unfavourable functional 
outcome.  
 
This present analysis included a larger number of RCTs than previous meta-analyses that 
showed DC improved survival and functional outcome (mRS  3) in patients with MCI but 
had a non-significant increase in proportion survivors with a favourable outcome defined as 
mRS  4. 13,24 Moreover, the definition of unfavourable outcome in this study (mRS > 4) was 
consistent with recent trials. 13,16,25 Although an mRS of 4 is usually identified as an 
unfavourable outcome, it is argued that considering the severity of a condition like MCI, 
recovery back to an mRS score of 1 or 2 is highly unlikely. Thus, we included an mRS of 4 
in the favourable outcome category, with results showing that early DC significantly reduced 
mortality but not unfavourable outcome at the end of follow-up.    
 
Importantly, outcome definition by researchers based on scales with a strong emphasis on 
motor functions may not reflect what is acceptable to the patient. 27 Thus, a more appropriate 
approach may involve conducting QoL assessments. A recent systematic review of QoL of 
patients following DC reported that most disabled patients (mRS >3) and carers were 
satisfied with their life and would opt to have the procedure again. 28,29 In addition, an 
analysis of quality-adjusted life-years (QALYS) in patients with MCI, reported more QALYs 
achieved with DC compared to BMT. 30 QoL assessments were lacking and of poor quality in 
the included studies. In addition, the QoL assessments in included RCTs were limited to 
patients that did not suffer from significant aphasia and neurological deficits. 13,19,21,21 Future 
studies that consider QoL and psychological states of patients are therefore warranted. 
 
The subgroup analysis stratified by age demonstrated a survival advantage in all age groups 
but did not find a significant association between DC and poor functional outcome. Previous 
meta-analyses have suggested age to be a strong predictor of poor functional outcome (mRS  
4) after DC in older patients. 31,32 The contrasting result could be due to the small number of 
studies in the present analysis that included older patients and the corresponding definition of 
t others as >70 
years, resulting in exclusion of patients between 60 and 70 years of age. 33 The DESTINY II 
trial provides the strongest evidence so far for DC in older patients. Although case fatality 
was comparable with younger patients, functional outcome was worse in the older patients 
compared to the younger group in previous trials (19% versus 4%). 24 Together, these results 
suggest that higher age may be an important predictor of poor outcome, though further 
studies are warranted to determine an age threshold, if one exists, for MCI patients.  
The timing of surgery is another important factor determining outcomes after MCI. Our 
analysis suggests that late DC (>48 hours) may not improve outcomes in MCI patients. This 
may be due to cerebral oedema increasing over time, reaching its peak and typically leading 
to death within 72-96 hours 34 thus, rendering later decompressive surgery ineffective. 
Notably, the HAMLET and HeADDFIRST trials allowed patients to receive DC up to 96 
hours. In these patients, no significant benefits were associated with later DC. Interestingly, 
in the HAMLET trial the mortality rate in the control group was significantly lower than the 
early DC group suggesting an underlying bias in assigning patients to the later DC group. 
Often patients undergoing surgery early do so because of rapid clinical deterioration. As 
such, pre-treatment prognostic factors may be accountable for the apparent lack of 
effectiveness of delayed DC. In addition, the lack of time subgroup analysis in 
HeADDFIRST trial makes the efficacy of delayed DC uncertain. 35 Accordingly, further 
randomised comparative studies are required to establish the effectiveness of delayed DC. 
Yet, since the effectiveness of early DC has been established, there is currently no reason to 
employ a watchful waiting approach (waiting for patient to deteriorate clinically) following a 
diagnosis of MCI. 
 
Some limitations of this study should be considered. First, the outcomes were based on mRS 
and GOS scales which neglected psychosocial functions and QoL. Second, the outcome 
assessment was not fully blinded in any study, which may have resulted in a degree of 
observer bias (though some trials did use partial blinding and combining the results of these 
trials argues against any major bias). Third, due to the small number of patients included in 
each individual trial, the conclusions derived from subgroup analyses on expected prognostic 
factors, such as age and timing to intervention, are not sufficiently powered to show 
quantitative differences between treatment effects. Fourth, although the technique of DC was 
standardised in most studies, the medical treatment was not consistent, and often left to the 
discretion of the attending physician. In the HAMLET trial for example, more patients in the 
control arm received osmotherapy than in the DC arm. Similarly, more DC patients were 
cared for in an NCC unit than control group. However, if osmotherapy was significantly 
effective, the outcomes differences between groups would have been smaller and 
insignificant. 
 
CONCLUSIONS 
Despite these limitations, this meta-analysis demonstrated a survival benefit associated with 
hemicraniectomy in patients with MCI both under and over the age of 60 years.  Yet, there 
was no significant difference favouring DC over BMT in terms of unfavourable outcome. As 
such, whether DC should be performed in patients over the age of 60 years remains 
controversial. Nonetheless, the likelihood of patients undergoing surgery is expected to 
increase. This comes with expected rise in morbidity and associated care burden. For 
clinicians, although challenging, it is imperative to communicate the potential range of 
outcomes and the expected QoL. Large, multicentre RCTs are required to determine efficacy 
of DC in older patients. These should incorporate long-term QoL assessment in addition to 
mortality and disability.  
 
Importantly, much can be learned about DC from MCI trials for other causes of ABI, as it is 
the only ABI condition with numerous RCTs and reviews. Despite this, the issue of benefit 
of DC has remained a contentious topic and perhaps RCTs may not be the optimal research 
methodology to address these questions. Continued prospective data collection for 
assessment of type and timing of DC in patients with different causes of ABI are 
recommended. Individual units across the UK could all collect such data on a nationally 
agreed/ approved database. 
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FIGURE LEGENDS 
 
 
Figure 1: PRISMA flow diagram for MCI studies. Adapted from Moher, et al., (2009). 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
statement.  
 
Figure 2a: Forest plot with OR estimating with 95% CI for the mortality outcome 
(defined as mRS=6) associated with DC versus BMT for studies grouped into RCTs and 
NRTs, and their pooled results at 3 months, 6 months, 12 months and 3 years follow-up. 
CI, confidence interval; DC: Decompressive craniectomy; BMT: best medical therapy; OR, 
odds ratio; mRS: modified Rankin Scale; IV: inverse variance; RCT: randomised controlled 
trials; NRTs: non-randomised trials. 
 
 
Figure 2b: Forest plot with OR estimating with 95% CI for unfavourable outcome 
(defined as mRS=5) associated with DC versus BMT for studies grouped into RCTs and 
NRTs, and their pooled results at 3 months, 6 months, 12 months and 3 years follow-up. 
CI, confidence interval; DC: decompressive craniectomy; BMT: best medical therapy; OR, 
odds ratio; mRS: modified Rankin scale; IV: inverse variance; RCT: randomised controlled 
trials; NRTs: non-randomised trials. 
 
Figure 3: Forest plot with OR estimating with 95%CI for (A) mortality outcome and 
(B) unfavourable outcome (defined as mRS=5) associated with DC versus BMT for 
individual studies and subgroup population stratified by age at 6 months follow-up.  
CI, confidence interval; DC: decompressive craniectomy; BMT: best medical therapy; OR, 
odds ratio; mRS: modified Rankin scale; IV: inverse variance. 
 
Figure 4: Funnel plot for assessment of publication bias. No obvious asymmetry was 
detected. OR: odds ratios, SE: standard error, logOR: Natural logarithm of the OR.  
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MCI Search Strategy 
CENTRAL/ MEDLINE Searched August 2018 
1. stroke$ or cerebral vascular or cerebrovasc$ or cva 
2. cerebrovascular disorders/ or cerebrovascular disease/ or brain ischemia/ or hypoxia-
ischemia, brain/ or carotid artery diseases/ or carotid artery, internal, dissection/ or 
 or stroke/ 
3. exp brain infarction/ 
4.  (brain or cerebral or intracranial) near3 (oedema or edema or swell*) 
5. MeSH descriptor Decompression, Surgical explode all trees 
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Table 2: OR estimates with corresponding 95% CI for mortality and unfavourable 
outcome in early and late DC 
Type 
of DC 
Follow-
up 
Outcome No. of 
studies 
No. of 
participant
s 
OR (95% CI) P value 
 
 
Early  
<48h 
3 
months 
mortality 2 120 0.10 [0.04, 0.23]* <0.00001 
mRS=5 2 84 0.51 [0.14, 1.86] 0.31 
6 
months 
mortality 9 686 0.22 [0.13, 0.39]* <0.00001 
mRS=5 6 416 0.89 [0.31, 2.56] 0.83 
12 
months 
mortality 6 310 0.15 [0.09, 0.26]* <0.00001 
mRS=5 2 106 0.36 [0.08, 1.57] 0.82 
3 years mortality 1 39 0.09 [0.02, 0.40]* 0.002 
mRS=5 1 39 2.71 [0.10, 70.65] 0.55 
 
 
Late 
DC 
>48h 
3 
months 
mortality 2 48 0.26 [0.02, 3.28] 0.30 
mRS=5 1 24 0.56 [0.11, 2.90] 0.49 
6 
months 
mortality 1 24 0.83 [0.16, 4.44] 0.83 
mRS=5 1 24 1.30 [0.23, 7.38] 0.77 
12 
months 
mortality 2 106 0.36 [0.08, 1.57] 0.17 
mRS=5 1 64 15.94 [0.86, 
296.1] 
0.06 
3 years mortality 1 24 0.57 [0.10, 3.18] 0.52 
mRS=5 1 24 Not estimable  
DC: Decompressive craniectomy, mRS= modified Rankin Scale, OR: odds ratio, CI: 
confidence interval. Bold font = statistical significance 
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OR= Odds ratio; IV= inverse variance; CI= confidence interval; NA= heterogeneity not 
applicable as only one study has been pooled; I2= heterogeneity 
*= statistical significance 
Table 3 Summary of results and sensitivity analyses for mortality and unfavourable 
outcome. 
Study 
subgroup 
No. of 
studies 
No. of 
patients 
Statistical 
method 
Effect estimate 
(95% Cl) 
P value I2 
Summary: mortality 
3 months 4 138 OR (IV, Random, 
95% CI) 
0.23 (0.07, 
0.71)* 
0.01  38% 
6 months 11 734 OR (IV, Random, 
95% CI) 
0.25 (0.15, 
0.43)* 
<0.00001 54% 
12 months 8 416 OR (IV, Random, 
95% CI) 
0.18 (0.11, 
0.29)* 
<0.00001 0 
3 years 1 63 OR (IV, Random, 
95% CI) 
0.21 (0.07, 
0.61)* 
0.004 NA 
 
Summary: unfavourable outcome 
3 months 3 108 OR (IV, Random, 
95% CI) 
0.53 (0.19, 
1.46) 
0.22 0 
6 months 8 464 OR (IV, Random, 
95% CI) 
1.03 (0.43, 
2.47) 
0.94 58% 
12 months 7 374 OR (IV, Random, 
95% CI) 
1.38 (0.47, 
4.11) 
0.56 39% 
3 years 1 63 OR (IV, Random, 
95% CI) 
3.20 (0.13, 
81.50) 
0.48 NA 
 
Sensitivity analyses for the mortality outcome excluding NRTs 
3 months 
RCTs 
1 24 OR (IV, Random, 
95% CI) 
0.83 [0.16, 
4.44] 
0.83 NA 
6 months 
RCTs 
6 277 OR (IV, Random, 
95% CI) 
0.22 [0.12, 
0.40]* 
<0.00001 18% 
12 months 
RCTs 
6 314 OR (IV, Random, 
95% CI) 
0.17 [0.10, 
0.28]* 
 
<0.00001 0% 
 
Sensitivity analyses for the unfavourable outcome excluding NRTs 
3 months 
RCTs 
1 24 OR (IV, Random, 
95% CI) 
0.56 [0.11, 
2.90] 
0.49 NA 
6 months 
RCTs 
6 277 OR (IV, Random, 
95% CI) 
1.79 [0.92, 
3.48] 
0.08 0 
12 months 
RCTs 
6 314 OR (IV, Random, 
95% CI) 
1.50 [0.36, 
6.22] 
0.58 52% 
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